BB Biotech AG Logo

BB Biotech AG

ISIN: CH0038389992 | Ticker: BION | LEI: 391200MBZQNPFHIVKO34
Sector: Health CareSub-Industry: Biotechnology
Country: Switzerland

About BB Biotech AG

Company Description

Since our foundation in 1993, we have offered investors direct access to a select portfolio of promising, fast growing and profitable biotech companies listed on stock markets around the world. Thanks to our strong track record over the years and our systematic strategy and clear focus, we have become one of the world’s largest biotech investors.

Biotechnology is one of the most attractive of any sector today with estimated annual growth in the double-digits. Mega trends such as increasing life expectancy and a westernized diet and lifestyle are powerful growth drivers. These mega trends have led to a tremendous increase in healthcare costs, which, in turn, only amplifies the need for more efficient and effective drugs.

Year founded

1993

Served area

Worldwide

Headquarters

Schwertstrasse 6, 8200 Schaffhausen – Switzerland

Financial statements

Download as Excel
Line item in (chf) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Cash and cash equivalents 30,707,000.00 6,816,000.00 2,835,000.00 1,948,000.00
Other Current Liabilities N/A 5,709,000.00 5,431,000.00 4,143,000.00
Line item in (chf) 01.01.2020/
01.01.2021
01.01.2021/
01.01.2022
01.01.2022/
01.01.2023
Revenue From Dividends 243,000.00 0.00 N/A
Profit (loss) 691,174,000.00 -404,808,000.00 -357,812,000.00
Line item in (chf) 01.01.2020 01.01.2021 01.01.2022 01.01.2023
Profit (loss) N/A 691,174,000.00 -404,808,000.00 -357,812,000.00
Increase (decrease) in cash and cash equivalents after effect of exchange rate changes N/A -23,891,000.00 -3,981,000.00 -887,000.00
Cash and cash equivalents 30,707,000.00 6,816,000.00 2,835,000.00 1,948,000.00

Please note that some sums might not add up.

Filings & Publications

2022

Report
Q1
H1
Q3
FY
Consolidated Report
GER / ENG
ENG
ENG
ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2021

Report
Q1
H1
Q3
FY
Consolidated Report
ENG / GER
GER / ENG
GER / ENG
GER
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2020

Report
Q1
H1
Q3
FY
Consolidated Report
ENG / GER
ENG / GER
GER / ENG
GER
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2019

Report
Q1
H1
Q3
FY
Consolidated Report
ENG / GER
ENG / GER
GER / ENG
GER / ENG
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

2018

Report
Q1
H1
Q3
FY
Consolidated Report
GER / ENG
ENG / GER
Corporate Governance Report
Company Presentation
Sustainability Report
Remuneration Report

Insider Trades

Date Trading entity / Person Association Trade type Volume
30.04.24 None Non-Executive member Buy CHF 41,450.00
25.03.24 None Non-Executive member Buy CHF 55,167.50
22.03.24 None Non-Executive member Buy CHF 105,927.16

Capital markets information

ISIN

CH0038389992

LEI

391200MBZQNPFHIVKO34

Sector

Health Care

Industry Group

Pharmaceuticals, Biotechnology & Life Sciences

Industry

Biotechnology

Sub-Industry

Biotechnology

Listed Stock Exchange

SIX Swiss Exchange

Contact Investor Relations department

Stay up to date

Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.